NasdaqGS:ROIVBiotechs
Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success
Why the brepocitinib data matters for Roivant Sciences (ROIV)
The Phase 3 VALOR trial results for brepocitinib in dermatomyositis, published in the New England Journal of Medicine and paired with an FDA Priority Review, put a key Roivant Sciences (ROIV) asset firmly in focus for investors.
See our latest analysis for Roivant Sciences.
Roivant’s recent brepocitinib milestones arrive after a 1 year total shareholder return of 155.49% and a 3 year total shareholder return of 259.35%. The share...